Is Opdivo approved for treating bladder cancer?

Yes, Opdivo is approved to treat bladder cancer. It is approved:

• as a first line treatment in combination with cisplatin and gemcitabine for adults with urothelial carcinoma (UC), the most common type of bladder cancer, that cannot be surgically removed (unresectable) or that has spread (metastatic)
• for locally advanced or metastatic urothelial cancer in adults whose disease has progressed during, following, or within 12 months of first-line or adjuvant platinum-containing chemotherapy. Approximately 50% of patients with bladder cancer do not respond to their first course of chemotherapy, and only 10 to 15% of those respond to second-line chemotherapy, and Opdivo represents another treatment option for these people.
• as additional treatment for adults with urothelial carcinoma that has a high risk of returning despite radical surgery.